日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Epigenetic Therapies

表观遗传疗法

Bourgeois, Wallace; Armstrong, Scott A; Heikamp, Emily B

Targeting the Menin-KMT2A interaction in leukemia: Lessons learned and future directions

靶向治疗白血病中的 Menin-KMT2A 相互作用:经验教训与未来方向

Perner, Florian; Gadrey, Jayant Y; Armstrong, Scott A; Kühn, Michael W M

Revumenib Revises the Treatment Landscape for KMT2A-r Leukemia

瑞伐美尼改变了KMT2A重排白血病的治疗格局

Heikamp, Emily B; Armstrong, Scott A

KAT6A and KAT7 Histone Acetyltransferase Complexes Are Molecular Dependencies and Therapeutic Targets in NUP98-Rearranged Acute Myeloid Leukemia

KAT6A 和 KAT7 组蛋白乙酰转移酶复合物是 NUP98 重排急性髓系白血病的分子依赖性和治疗靶点

Michmerhuizen, Nicole L; Heikamp, Emily B; Iacobucci, Ilaria; Umeda, Masayuki; Arthur, Bright; Mishra, Vibhor; Park, Chun Shik; Di Giacomo, Danika; Hiltenbrand, Ryan; Gao, Qingsong; Radko-Juettner, Sandi; Lott, Josi; Martucci, Cynthia; Subramanyam, Varsha; Hatton, Charlie; Wenge, Daniela V; Baviskar, Pradyuamna; Portola, Pablo; Claquin, Aurelie; Chandra, Bappaditya; Baggett, David W; Khalighifar, Ali; Huang, Hongling; Zhou, Peipei; Long, Lingyun; Shi, Hao; Sun, Yu; Papachristou, Evangelia K; Sekhar Reddy Chilamakuri, Chandra; de Luna Vitorino, Francisca N; Gongora, Joanna M; Wu, Huiyun; Pounds, Stanley B; Janke, Laura J; Kentsis, Alex; D'Santos, Clive S; Garcia, Benjamin A; Kriwacki, Richard W; Chi, Hongbo; Klco, Jeffery M; Armstrong, Scott A; Mullighan, Charles G

An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4-mediated ferritinophagy as a dependence in Tet2-deficient hematopoiesis

体内条形码 CRISPR-Cas9 筛选发现 Ncoa4 介导的铁蛋白自噬是 Tet2 缺陷型造血的依赖性过程。

Loke, Justin; Kim, Peter G; Nguyen, Thuy T P; Boileau, Meaghan; McConkey, Marie; Miller, Aidan; Shin, Wesley; Hergott, Christopher B; Ericsson, Maria; Nordstrom, Anja; Llopis, Paula Montero; Armstrong, Scott A; Mancias, Joseph D; Ebert, Benjamin L

p300/CBP is an essential driver of pathogenic enhancer activity and gene expression in Ewing sarcoma.

p300/CBP 是尤文氏肉瘤中致病增强子活性和基因表达的重要驱动因素。

Godfrey Laura C, Regalado Brandon, Schweber Sydney R, Hatton Charles, Wenge Daniela V, Wen Yanhe, Boileau Meaghan, Wessels Maria, Qi Jun, Ott Christopher J, Stegmaier Kimberly, Rivera Miguel N, Armstrong Scott A

High-throughput diversification of protein-ligand surfaces to discover chemical inducers of proximity

利用高通量方法对蛋白质-配体表面进行多样化修饰,以发现邻近效应的化学诱导剂。

Shaum, James B; Muñoz I Ordoño, Miquel; Steen, Erica A; Wenge, Daniela V; Cheong, Hakyung; Hunkeler, Moritz; Bilotta, Eric M; Rutter, Zoe; Barta, Paige A; Thornhill, Abby M; Milosevich, Natalia; Hargis, Lauren M; Janowski, Jordan; Bishop, Timothy R; Carter, Trever R; da Camara, Bryce; Hinterndorfer, Matthias; Dada, Lucas; He, Wen-Ji; Offensperger, Fabian; Furihata, Hirotake; Schweber, Sydney R; Hatton, Charlie; Wen, Yanhe; Cravatt, Benjamin F; Engle, Keary M; Donovan, Katherine A; Melillo, Bruno; Kitamura, Seiya; Ciulli, Alessio; Armstrong, Scott A; Fischer, Eric S; Winter, Georg E; Erb, Michael A

CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype-specific Vulnerability in IDH2- and TET2-mutant Cells.

在原代造血干细胞中进行的 CRISPR 依赖性筛选发现 KDM3B 是 IDH2 和 TET2 突变细胞中的基因型特异性脆弱性

Waarts Michael R, Mowla Shoron, Boileau Meaghan, Martinez Benitez Anthony R, Sango Junya, Bagish Maya, Fernández-Maestre Inés, Shan Yufan, Eisman Shira E, Park Young C, Wereski Matthew, Csete Isabelle, O'Connor Kavi, Romero-Vega Angelica C, Miles Linde A, Xiao Wenbin, Wu Xiaodi, Koche Richard P, Armstrong Scott A, Shih Alan H, Papapetrou Eirini P, Butler Jason M, Cai Sheng F, Bowman Robert L, Levine Ross L

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias

强效、选择性menin-KMT2A抑制剂JNJ-75276617(bleximenib)在KMT2A和NPM1改变的白血病中的临床前疗效

Kwon, Min Chul; Thuring, Jan Willem; Querolle, Olivier; Dai, Xuedong; Verhulst, Tinne; Pande, Vineet; Marien, Ann; Goffin, Dries; Wenge, Daniela V; Yue, Hong; Cutler, Jevon A; Jin, Cyrus; Perner, Florian; Hogeling, Shanna M; Shaffer, Paul L; Jacobs, Frank; Vinken, Petra; Cai, Wei; Keersmaekers, Vikki; Eyassu, Filmon; Bhogal, Balpreet; Verstraeten, Karin; El Ashkar, Sara; Perry, Jennifer A; Jayaguru, Prathiba; Barreyro, Laura; Kuchnio, Anna; Darville, Nicolas; Krosky, Daniel; Urbanietz, Gregor; Verbist, Bie; Edwards, James P; Cowley, Glenn S; Kirkpatrick, Robert; Steele, Ruth; Ferrante, Lucille; Guttke, Christina; Daskalakis, Nikki; Pietsch, E Christine; Wilson, David M; Attar, Ricardo; Elsayed, Yusri; Fischer, Eric S; Schuringa, Jan Jacob; Armstrong, Scott A; Packman, Kathryn; Philippar, Ulrike

Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML

在KMT2A-r和NPM1c AML的临床前模型中,美西格胺单独使用或与menin抑制剂联合使用均有效。

Bourgeois, Wallace; Cutler, Jevon A; Aubrey, Brandon J; Wenge, Daniela V; Perner, Florian; Martucci, Cynthia; Henrich, Jill A; Klega, Kelly; Nowak, Radosław P; Donovan, Katherine A; Boileau, Meaghan; Wen, Yanhe; Hatton, Charlie; Apazidis, Athina A; Olsen, Sarah Naomi; Kirmani, Nadia; Pikman, Yana; Pollard, Jessica A; Perry, Jennifer A; Sperling, Adam S; Ebert, Benjamin L; McGeehan, Gerard M; Crompton, Brian D; Fischer, Eric S; Armstrong, Scott A